Josep M. Tabernero
Universitat de Vic - Universitat Central de Catalunya · 2,960 works · 130,146 citations · h-index 150
Top works
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
- The landscape of somatic copy-number alteration across human cancers
- The consensus molecular subtypes of colorectal cancer
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
- ESMO-Magnitude of Clinical Benefit Scale version 1.1